📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding PVLA

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Steve Cohen Point72 Asset Management	88.2K	$11.0M	0.01%	Mar 2026
Jim Simons Renaissance Technologies LLC	18.0K	$2.2M	0.00%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management used phrases like 'as energized as we've ever been', 'transformative period', 'exceeded our original target by more than 25%', and 'thrilled' to describe progress on key trials and leadership hires. They provided specific numbers such as 51 subjects enrolled (exceeding 40 target), $70.4M cash, and $9.3M quarterly operating expense, reinforcing a data-backed optimistic tone.

Q3 2025

Confident Specific

Management repeatedly used language like 'on track', 'over-enrolled', 'strong momentum', and provided specific thresholds (30% improvement) and clear timelines (TOIVA data next month, SELVA data Q1 2026). The tone is forward-looking with no hedging on pipeline milestones.

Q4 2025

Confident Specific

Management repeatedly uses phrases like 'landmark year', 'exceeded our predefined upside case across every dimension', 'well-positioned', and 'exceptional' to describe results and outlook. They provide concrete numbers on patient populations and financial runway.

Q1 2026 latest

Confident Specific

Management used overwhelmingly positive and precise language: 'decisively positive phase III results', 'robust evidence package', 'strong capital base', '98% of physicians would consider first-line'. They repeatedly cited specific numbers (95% improvement, 73% improvement, >$1B peak sales) and clear timelines (NDA H2 2026, approval H1 2027). The tone was assured and detailed, without hedging.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is materially stronger after this call. Positive phase III SELVA data, a $230M financing that removes near-term dilution risk, and clear regulatory/commercial milestones (NDA filing, pre-NDA meeting, launch prep) de-risk the lead program. Management's specific guidance on pricing ($100k–$200k), peak sales (>$1B), and physician adoption (98% first-line) suggest high conviction. Pipeline expansion into four other indications adds optionality. Key watch items: the FDA pre-NDA meeting outcome (rolling submission?), the Phase III cVM trial start, DSAP Phase II initiation, and any competitive updates from Quoin. Overall, Palvella appears well-positioned for a potential 2027 launch, but execution on NDA and commercial build-out remains critical.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Palvella targets first FDA approval for QTORIN rapamycin in mLM with >$1B peak sales

Revenue & Profitability

As of Q1 2026, Palvella held $261.9 million in cash, cash equivalents, and short-term investments, following a $230 million upsized equity offering in February 2026. The company has no reported revenue and expects its cash to fund operations through cash flow break-even, assuming a potential FDA approval and launch in the first half of 2027.

Outlook

Management sees significant unmet need in rare skin diseases where patients have historically been overlooked, with limited or no treatment options. They believe first-in-disease therapies can expand markets through improved diagnosis and referral patterns. Market research indicates 98% of physicians would consider QTORIN rapamycin first-line therapy for mLM, and 96% favor targeted topical over systemic approaches for pediatric patients.

Growth Drivers

Key growth levers include the upcoming NDA submission for QTORIN rapamycin in mLM in H2 2026 and potential FDA approval in H1 2027. Additional catalysts: Phase III initiation for cutaneous venous malformations in H2 2026, Phase II LOTU trial for angiokeratomas (dosing ahead of schedule, data H2 2027), Phase II DSAP trial start in H2 2026, and planned expansion to six indications by year-end with a new QTORIN product candidate and a fourth rapamycin indication.

Balance Sheet & CapEx

Not discussed in detail. Management is investing in commercial infrastructure for a potential launch, targeting a 30-40 person sales force and an expanded MSL team, with plans to have the field team in place before the PDUFA date.

Margins

Not discussed in this earnings call.

Key Risks

Key risks include regulatory uncertainties: the pre-NDA meeting with the FDA must align on an efficient submission path; potential requirement for placebo-controlled trials in certain indications; execution risk in patient enrollment for ongoing and planned trials; and the emergence of competitor therapies. Management also highlighted the need to identify and appropriately select patients for clinical studies.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-04

Q2 2026 saw major milestones, including positive phase III results for QTORIN rapamycin in mLM, rolling NDA submission, and a $230M capital raise. The company is well-funded for launch and pipeline expansion, with multiple rare disease programs advancing and strong physician and payer interest.

Q1 2026 Q1 2026 2026-05-07

Positive phase III results for QTORIN rapamycin in mLM and a $230M financing position the company for a potential first FDA approval and U.S. launch in 2027, with a robust pipeline and strong physician support for first-line use.

Q4 2025 Q4 2025 2026-03-31

Major milestones achieved in 2025 include positive phase III data, pipeline expansion, and a $230M financing, positioning the company for NDA submission and potential FDA approval in 2027. Strong cash reserves fully fund lead programs and commercial launch plans.

Q3 2025 Q3 2025 2025-11-11

Advanced late-stage pipeline with over-enrollment in key trials and expanded rare disease programs. Ended Q3 with $63.6M cash, supporting operations into H2 2027. Multiple clinical and regulatory milestones expected in the next 18 months.

Q2 2025 Q2 2025 2025-08-14

Key clinical milestones achieved with full SELVA Phase 3 enrollment and ongoing TOIVA Phase 2 trial. Cash runway extends into 2027, supporting multiple upcoming data readouts and new program launches. Market research and regulatory progress reinforce strong commercial potential.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.